{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"LAGOON","nct_id":"NCT05153239","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=lagoon-nct05153239. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)","label":"Lurbinectedin","type":"EXPERIMENTAL"},{"description":"Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):\n\n* Irinotecan (Day 1 and Day 8)\n* Lurbinectedin (Day 1)","label":"Lurbinectedin plus Irinotecan","type":"EXPERIMENTAL"},{"description":"Best Investigator's choice prior to randomization between:\n\n* Irinotecan on Day 1 q3wk\n* Topotecan on Days 1-5 q3wk","label":"Control arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-04-10","type":"ACTUAL"},"conditions":["Relapsed Small Cell Lung Cancer"],"enrollment":{"count":705,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"Lurbinectedin","otherNames":["PM01183"],"type":"DRUG"},{"name":"Irinotecan","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"},{"name":"Lurbinectedin","otherNames":["PM01183"],"type":"DRUG"}],"last_update":"2026-10-21","lead_sponsor":"PharmaMar","official_title":"A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-04-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From the date of randomization to the date of death or last contact, up to 39 months"}],"references":[{"citation":"Falcon A, Ponce S, Cote GM, Gil A, Lin JJ, Bockorny B, Martinez J, Kahatt C, Martinez S, Zubiaur P, Siguero M, Cullell-Young M, Jimenez J, Zugazagoitia J, Paz-Ares L. Phase I results on the efficacy, safety and pharmacokinetics of lurbinectedin and irinotecan in advanced solid tumors. Invest New Drugs. 2025 Aug;43(4):955-967. doi: 10.1007/s10637-025-01583-y. Epub 2025 Sep 18.","pmid":"40963055","type":"DERIVED"}],"start_date":{"date":"2022-07-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)","url":"https://clinicaltrials.gov/study/NCT05153239"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/lagoon-nct05153239"}